LOS ANGELES–(BUSINESS WIRE)–The Law Offices of Frank R. Cruz announces an investigation of MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
IF YOU ARE AN INVESTOR WHO LOST MONEY ON MOONLAKE (MLTX) CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.
What Is The Investigation About?
On September 28, 2025, MoonLake Immunotherapeutics announced disappointing Phase 3 results for its only drug candidate, sonelokimab (“SLK”), revealing that SLK failed to match the efficacy of its competitor, Union Chimique Belge’s bimekizumab-bkz. The Company had repeatedly promoted SLK’s nanobody structure as superior to other monoclonal antibodies—while allegedly failing to disclose it targeted the same molecules and lacked proven advantages.
Following the news, MoonLake’s stock fell $55.74, or 89.9%, to close at $6.24 per share on September 29, 2025, and thereby harming investors.
Contact Us To Participate or Learn More:
If you purchased MoonLake securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: info@frankcruzlaw.com
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.
If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz
310-914-5007
fcruz@frankcruzlaw.com
www.frankcruzlaw.com
